Emergent receives $52.7M contract modification for ACAM2000 vaccine supply.
Emergent BioSolutions announced a $52.7 million contract modification from the U.S. government to supply ACAM2000 vaccine. This award supports biodefense preparedness and reinforces the company's financial outlook.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day